• Molecular NamePenicillamine
  • Synonymbeta-Thiovaline; beta,beta-Dimethylcysteine; D-Mercaptovaline; D-Penamine; D-Penicilamine; D-Penicillamine; D-Penicyllamine; Dimethylcysteine; L-Penicillamine; PCA; Penicilamina [INN-Spanish]; Penicillamin; Penicillamina [DCIT]; Penicillaminum [INN-Latin]; Penicilllamine
  • Weight149.214
  • Drugbank_IDDB00859
  • ACS_NO52-67-5
  • Show 3D model
  • LogP (experiment)-1.78
  • LogP (predicted, AB/LogP v2.0)-1.83
  • pka1.8, 7.9, 10.5
  • LogD (pH=7, predicted)-1.84
  • Solubility (experiment)111 mg/mol
  • LogS (predicted, ACD/Labs)(ph=7)0.31
  • LogSw (predicted, AB/LogsW2.0)78.84
  • Sw (mg/ml) (predicted, ACD/Labs)304.44
  • No.of HBond Donors3
  • No.of HBond Acceptors3
  • No.of Rotatable Bonds2
  • TPSA102.12
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA pharmaceutical of the chelator class.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability50.0
  • Protein binding90.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic
  • Half life2~6 h
  • ExcretionRenal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThe most common adverse events to Penicillamine are vomiting, anorexia, fever, diarrhea, lethargy, and rash.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A